Copied
 
 
Formål
Formål
Selskabets formål er produktion og handel og anden dermed i forbindelse stående virksomhed.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 19.12.2012 (4149 dage).
Ingen historik.
Status
Virksomhedsstatus
NORMAL.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 01.12.2012 (4167 dage).
Ingen historik.
Branche
Branche
Fremstilling af andre kemiske produkter i.a.n (205900).
Sidst opdateret den 21.03.2018 og angivet som gældende fra 01.01.2018 (2310 dage).
HistorikStartStop
Fremstilling af andre kemiske produkter i.a.n (205900)01.01.2018
Fremstilling af farmaceutiske råvarer (211000)01.01.201331.12.2017
Fremstilling af andre organiske basiskemikalier (201400)01.12.201231.12.2012
Revision
Revisionfravalgt
false.
Sidst opdateret den 11.03.2015 og angivet som gældende fra 01.12.2012 (4167 dage).
Ingen historik.
Revisor
Revisor
KPMG P/S
Sidst opdateret den 12.10.2023 og angivet som gældende fra 07.07.2023 (297 dage).
HistorikStartStop
KPMG P/S07.07.2023
EY Godkendt Revisionspartnerselskab20.04.201507.07.2023
Datoselskabet af den 3. juli 2016 RVT P/S18.09.201320.04.2015
Datoselskabet af den 3. juli 2016 RVT P/S01.12.201218.09.2013
Form
Virksomhedsform
60.
Sidst opdateret den 14.12.2012 og angivet som gældende fra 01.12.2012 (4167 dage).
Ingen historik.
Kontakt
Ingen nuværende registrering.
Ingen historik.
Telefon
Ingen nuværende registrering.
Ingen historik.
Navne
Binavne
Binavne
DNA Technology A/S.
Sidst opdateret den 08.08.2016 og angivet som gældende fra 08.08.2016 (2821 dage).
Ingen historik.
Tegningsregel
Tegningsregel
Selskabet tegnes af en direktør i forening med bestyrelsens formand eller af den samlede bestyrelse.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 19.12.2012 (4149 dage).
Fortolkning (2 tegningsmuligheder)
1 direktør + formanden
bestyrelsen
Ingen historik.
Ansatte
29.04.2024
Kapital
29.04.2024
Fra årsrapport
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:EY Godkendt Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:30700228
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse C, mellemstor virksomhed
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Independence We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.
Konklusion (revision):We have audited the financial statements of LGC Biosearch Technologies A/S for the financial year 1 April 2022 - 31 March 2023, which comprise income statement, balance sheet, statement of changes in equity, cash flow statement and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 March 2023 and of the results of the Company's operations as well as the cash flows for the financial year 1 April 2022 - 31 March 2023 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Management is responsible for the Management's review. Our opinion on the financial statements døs not cover the Management's review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act. Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.
Bibranche
Ingen nuværende registrering.
Ingen historik.
Børsnoteret
29.04.2024
Ingen nuværende registrering.
Ingen historik.
Hjemmeside
29.04.2024
Ingen nuværende registrering.
Ingen historik.